ÍÆ¼ö¸øºÃÓÑ ÉÏһƪ | ÏÂһƪ

Èý½×ÌÝÕòÍ´ÖÎÁÆÔÚ½éÈë¿ÆµÄÁÙ´²Ó¦ÓÃ

 [ÕªÒª]Ä¿µÄ ·ÖÎöÈý½×ÌÝÕòÍ´ÖÎÁƶԽéÈë¿ÆÊÕÖεĶñÐÔÖ×Áö°éÌÛÍ´ÕßµÄÁÙ´²Ó¦Óü°°²È«ÐÔ¡£·½·¨ ¶ñÐÔÖ×Áö°éÌÛÍ´Õß80Àý£¬¸ù¾ÝÌÛÍ´³Ì¶È£¬·Ö±ð¸øÒÔ²»Í¬½×ÌݵÄÕòÍ´ÖÎÁƲ¢¹Û²ìÁÙ´²ÁÆÐ§¼°²»Á¼·´Ó¦£¬ÓÃÊý×ÖÆÀ·Ö·¨ÆÀ¹ÀÌÛÍ´³Ì¶È¼°Éú»îÖÊÁ¿¡£¸ù¾ÝÖ×ÁöÇé¿ö£¬Ê©Ðв»Í¬µÄ½éÈëÖÎÁÆ¡£½á¹û ÖÎÁÆÇ°ÌÛÍ´³Ì¶ÈÆÀ·Ö¾ùֵΪ6.86£¬ÖÎÁƺóµÚ3£¬7£¬14ÌìÌÛÍ´³Ì¶ÈÆÀ·Ö·Ö±ð½µÖÁ3.12£¬2.40£¬2.01£¬ÌÛÍ´³Ì¶ÈÏÔÖø¼õÇᣨP<0.01£©£¬×ÜÓÐЧÂÊΪ98.75%¡£ÖÎÁƺóÉú»îÖÊÁ¿Ã÷ÏÔ¸ÄÉÆ£¨P<0.01£©¡£²»Á¼·´Ó¦×Ü·¢ÉúÂÊÔ¼41.25%£¬¶àΪÇá¶È£¬Ö÷ҪΪ±ãÃØ¡¢¶ñÐÄ¡¢Å»Í¡¢Í·ÔΡ¢ÊÈ˯£¬Î´¼ûºôÎüÒÖÖÆµÈÑÏÖØ²»Á¼·´Ó¦¡£½áÂÛ ÕòÍ´ÖÎÁƶԽéÈë¿Æ°©Í´»¼ÕßÖØÒªÊµÓã¬Ó¦¸øÒÔ»ý¼«µÄ¹Ø×¢¼°ÖÎÁÆ£¬ËæÊ±ÆÀ¹ÀÕòÍ´ÁÆÐ§£¬µ÷ÕûÓÃÒ©¼ÁÁ¿£¬¾ÀÕý²»Á¼·´Ó¦¡£

[¹Ø¼ü´Ê] ÌÛÍ´/¶ñÐÔÖ×Áö  ÕòÍ´ÖÎÁÆ/½éÈëÖÎÁÆ

[Abstract]Objective To analyse the clinical effect and safety of the three steps analgesic ladder for cancer pain in interventional radiology department. Methods Eighty cases of malignant tumor patients were administrated by using the analgesic according to different degree. The clinical effect and side effects were recorded. The degree of pain and quality of life were evaluated by NRS.  Results  Baseline mean pain intensity was 6.86 before treatment. On days 3,7,14, the mean scores of pain were decreased to 3.12, 2.40 and 2.01,respectively (P<0.01). The effective rate was 98.75%. The quality of life was significantly improved after treatment (P<0.01). The total rate of side effects was 41.25%, including constipation, nausea, vomiting, dizziness and sedation. The respiratory depression and other severe side effects were not observed. Conclusion The three steps analgesic ladder plays an importment role for patients with cancer in interventional radiology department.

[Key Words] pain/malignant tumors; antalgic therapy/ interventional therapy

ÌÛÍ´ÊǶñÐÔÖ×ÁöÍíÆÚ³£¼ûµÄÁÙ´²Ö¢×´£¬Ò²ÊÇÓ°Ï컼ÕßÉú»îÖÊÁ¿µÄÖØÒªÒòËØ¡£WHO°Ñ°©Í´ÖÎÁÆÌáµ½ÁËÖØÒªºÍÓÅÏȽâ¾öµÄµØÎ»£¬²¢Ìá³öÁËÔÚ2000ÄêʹȫÊÀ½çµÄ°©Ö¢²¡È˲»Í´µÄÕ½ÂÔÄ¿±ê[1]¡£½üÈýÄêÀ´ÎÒ¿ÆÊÕÖεĶñÐÔÖ×Áö°éÌÛÍ´ÕßÔ¼Õ¼30-40%£¬ÊÕ¼¯ÆäÖÐ80Àý½øÐÐÁÙ´²ÖÎÁÆ·ÖÎö¼°²»Á¼·´Ó¦×ܽᡣ

×ÊÁÏÓë·½·¨£º

1 ²¡Àý×ÊÁÏ£º 80Àý¶ñÐÔÖ×Áö°éÌÛÍ´Õߣ¬ÄÐ57Àý£¬Å®23Àý£¬ÄêÁä31Ëê-86Ë꣬ÖÐλÄêÁä62Ëê¡£ÁÙ´²Õï¶ÏÖ÷ҪΪÏû»¯µÀ¶ñÐÔÖ×Áö£º¸Î°©18Àý£¬ÒÈÏÙ°©21Àý£¬µ¨¹Üµ¨ÄÒ°©17Àý£¬Î¸³¦Ö×Áö¸¹Ç»Áܰͽá×ªÒÆÁö24Àý£¬°é¹Ç×ªÒÆ°©7Àý¡£È«²¿²¡Àý·ûºÏ½éÈëÊÖÊõÖ¸Õ÷£¬¸ù¾ÝÖ×ÁöÇé¿ö½ÓÊܲ»Í¬µÄ½éÈëÖÎÁÆ¡£ÖÎÁÆÇ°ÌÛÍ´³Ì¶ÈÆÀ·Ö£¨NRS£©£º4-10£¬¾ùÖµ£¨x £©6.86£¬ÇáÖжÈÌÛÍ´Õß43Àý£¨53.75%£©£¬ÖضÈÌÛÍ´Õß37Àý£¨46.25%£©£¬¹Ç×ªÒÆ°©ÓëÌÛÍ´³Ì¶ÈÃ÷ÏÔÏà¹Ø£¬°é¹Ç×ªÒÆÕß¾ùÎªÖØ¶ÈÌÛÍ´¡£

2 ÖÎÁÆ·½·¨£º Ñ¡Óöþ½×ÌÝÒ©ÎïÑÎËáÇúÂí¶à»ºÊÍÆ¬£¨ÆæÂü¶¡£©£¬Èý½×ÌÝÒ©ÎïÑÎËáôÇ¿¼Íª¿ØÊÍÆ¬£¨°ÂÊ©¿µ¶¨£©£¨ÉÏÁ½Ò©Îª±±¾©Ã˵ÙÖÆÒ©£©ºÍ·ÒÌ«Äá͸ƤÌù¼Á£¨¶àÈ𼪣©£¨Î÷°²ÑîÉ­ÖÆÒ©£©¡£¸ù¾ÝÌÛÍ´³Ì¶È·Ö±ð¸øÒÔ²»Í¬½×ÌݵÄÕòÍ´ÖÎÁÆ£¬Ã¿24СʱÆÀ¹ÀÕòÍ´ÁÆÐ§£¬ÕòÍ´ÖÎÁÆÄ¿±ê£ºÌÛÍ´³Ì¶ÈÆÀ·Ö<3£¬ËæÊ±µ÷ÕûÓÃÒ©¼°¼ÁÁ¿¡£¸ù¾Ý²»Á¼·´Ó¦¼°³Ì¶È£¬·Ö±ð¸øÒÔ»ºÐº¼Á¼°Ö¹Í¼Á¡£
Ö×ÁöÖÎÁÆ£º¸ù¾Ý²¡ÇéÊ©Ðв»Í¬µÄ½éÈëÖÎÁÆ£¬58Àý¶ñÐÔ¹£×èÐÔ»ÆðãÕߣ¬Ðе¨¹ÜÒýÁ÷Êõ»òµ¨¹ÜÖ§¼ÜÖÃÈëÊõ£¬22ÀýÐÐÖ×Áö˨Èû»¯ÁÆÊõ¡£¶ÔÊõÖб©·¢Í´Óü´ÊÍÂð·ÈÕòÍ´ÖÎÁÆ¡£

3 ¹Û²ìÏîÄ¿£º(1)ֹʹÁÆÐ§£ºÓÃ0-10Êý×ÖÆÀ·Ö·¨£¨NRS£©ÆÀ¹À£¬ÖÎÁÆÇ°ºó×ÔÉí¶ÔÕÕ¡£(2)Éú»îÖÊÁ¿£º¹Û²ìʳÓû¡¢¾«Éñ¡¢Ë¯Ãß¡¢ÈÕ³£»î¶¯¡¢ÓëÈ˽»Íù¹²5ÏîÉú»îÖÊÁ¿Ö¸±ê£¬²ÉÓÃ1-5Êý×ÖÆÀ·Ö·¨ÆÀ¹À¡£5ÏîÖ¸±ê¹²25·Ö£¬>16ΪÉú»îÖÊÁ¿Á¼ºÃ£¬<15ΪÉú»îÖÊÁ¿²î¡£(3)²»Á¼·´Ó¦£º¼Í¼һÏîÖ÷ÒªµÄ²»Á¼·´Ó¦¡£(4)½éÈëÊÖÊõÖÐʹÓü´ÊÍÂð·ÈµÄƵÂʼ°¼ÁÁ¿¡£
4 Ó¦ÓÃSPSSͳ¼ÆÈí¼þ½øÐÐͳ¼ÆÑ§´¦Àí¡£

½á¹û£º
1. 80ÀýÑ¡ÔñÓÃÒ©Çé¿ö£¨¼û±í1£©
±í1  80Àý²¡È˵ÄÓÃÒ©Çé¿ö

Ò©Îï

µÚ1d

µÚ3d

µÚ7d

µÚ14d

×î´óÓÃÁ¿

ÆæÂü¶¡

12

8

4

4

400mg/24h

°ÂÊ©¿µ¶¨

30

32

32

32

80mg/24h

¶àÈð¼ª

38

40

44

44

37.5mg/72h


2.ÕòÍ´ÁÆÐ§£º£¨¼û±í2£©
±í2  80Àý²¡È˵ÄÕòʹЧ¹û

NRS (x¡Às)

  ÖÎÁÆÇ°     ÖÎÁƺó3d       ÖÎÁƺó7d   ÖÎÁƺó14d   ×ÜÓÐЧÂÊ

6.86¡À1.42   3.12¡À1.34    2.40¡À1.15   2.01¡À1.12   98.75%

ÖÎÁƺóÓëÖÎÁÆÇ°±È½ÏÌÛÍ´³Ì¶ÈÏÔÖø¼õÇᣨP<0.01£©£¬°ÂÊ©¿µ¶¨ºÍ¶àÈð¼ªÕòÍ´ÁÆÐ§ÎÞ²î±ð¡£ÆæÂü¶¡ÕòÍ´ÁÆÐ§²îʱ£¬¿É»»ÓðÂÊ©¿µ¶¨ºÍ¶àÈ𼪡£

3.Éú»îÖÊÁ¿£ºÖÎÁÆÇ°Éú»îÖÊÁ¿Á¼ºÃµÄ²¡ÀýÕ¼37.5%£¨30/80£©£¬ÖÎÁƺóµÚ7ÌìºÍµÚ14Ìì·Ö±ðÔöÖÁ75%£¨60/80£©ºÍ78.75%£¨63/80£©£¬ÖÎÁÆÇ°ºóÉú»îÖÊÁ¿²î±ðÏÔÖø£¨P<0.01£©¡£²¡È˳öԺʱ¾ùÑ¡Ôñ¼ÌÐøÖÎÁÆ¡£

4.²»Á¼·´Ó¦£ºÓÃÒ©ºó33Àý£¨41.25%£©³öÏÖ²»Á¼·´Ó¦£¬¶àΪÇá¶È£¬±ãÃØ19Àý£¨23.75%£©£¬¶ñÐÄÅ»ÍÂ8Àý£¨10%£©£¬Í·ÔÎÊÈ˯6Àý£¨7.5%£©£¬Î´¼ûºôÎüÒÖÖÆµÈÑÏÖØ²»Á¼·´Ó¦¡£ÎÞ¾«ÉñÒÀÀµÐÔ¼°Ò©ÎïÀÄÓò¡Àý¡£

5.ÕòÍ´ÖÎÁƲ¡Àý½éÈëÖÎÁÆÊÖÊõÖм´ÊÍÂð·ÈʹÓÃÂÊ32.5%£¨26/80£©£¬Ëæ»ú³éÈ¡ÊõǰÎÞÕòÍ´ÖÎÁÆ80Àý×÷Ϊ¶ÔÕÕ£¬½éÈëÊÖÊõÖм´ÊÍÂð·ÈʹÓÃÂÊΪ77.5%£¨62/80£©£¬Á½×é¼ä²î±ðÏÔÖø£¨P<0.01£©¡£ÕòÍ´ÖÎÁÆ×éÊõÖÐÂð·ÈʹÓÃÁ¿¾ùΪ10mg£¨1´Î£©,¶ÔÕÕ×鲿·Ö²¡ÀýÓÃÖÁ20mg£¨2´Î£©¡£

ÌÖÂÛ£º
1. ÖØÊÓÕòÍ´ÖÎÁÆ£º°©Í´¸ø»¼Õß´øÀ´Éú»îÐÅÐĵÄɥʧ£¬¶ÔÖÎÁƲ»ÐÅÈΡ£ÌÛÍ´Ô½ÖØ£¬¶Ô»¼ÕßµÄÉú»îÖÊÁ¿Ó°ÏìÔ½´ó[2]¡£WHOÌᳫµÄÄ¿±ê£º°©Ö¢ÌÛÍ´Ó¦µ±Êܵ½ÖØÊÓ£¬ÊÇ¿ÉÒÔÖÎÁƵģ¬Í¨¹ý±È½Ï¼òµ¥µÄ·½·¨¼´Èý½×ÌÝֹʹÁÆ·¨¿Éʹ80%µÄ²¡ÈËÌÛÍ´µÃµ½»º½â£¬ÒµÒѱ»Ö¤Ã÷ÊÇ¿ÉÐеÄ[1]¡£ÌÛʹʹÊÖÊõºó賦µÀ´¦ÓÚ¸ßÓ¦¼¤×´Ì¬£¬Èç´¦Àí²»¼°Ê±£¬¿É¼ÓÖØÓ¦¼¤ÐÔÀ£ÑñµÄ·¢Éú¡£ÐÄѪ¹Üϵͳ´¦ÓÚ¸ßÕÅÁ¦×´Ì¬£¬Ê¹ÑªÑ¹Éý¸ß£¬ÐÄÂʼӿ죬²»ÀûÓÚÊõºó×éÖ¯Æ÷¹Ù¹©Ñª£¬ÓÈÆäÊǶÔÒûʳ˯ÃßµÄÓ°Ï죬¼´Ó°Ï컼ÕßµÄÉú»îÖÊÁ¿£¬ÓÖ²»ÀûÓÚÊõºóµÄ»Ö¸´£¬Ö±½ÓÓ°ÏìÊÖÊõÁÆÐ§¡£¿É¼ûÕòÍ´ÖÎÁÆÖ®ÖØÒª¡£
2. ÕòÍ´Ò©ÎïµÄÑ¡Ôñ£º°¢Æ¬ÀàÒ©ÎïÔÚÈ«ÊÀ½ç·¶Î§ÄÚÈÔÊÇÖÎÁÆÖÐÖØ¶È°©Í´µÄÊ×Ñ¡ÓÃÒ©[3]¡£ËäȻֹʹҩÎï¼°·ÇÒ©ÎïÖÎÁÆ·½·¨ºÜ¶à£¬µ«¶ÔÓÚÖÐÖØ¶È°©Í´»¼Õߣ¬°¢Æ¬Ààֹʹҩ¾ßÓÐÎÞ¿ÉÈ¡´úµÄÖØÒªµØÎ»[4]¡£Í¨¹ý½üÄêÀ´ÕòÍ´ÖÎÁƵÄÌå»á£º¶àÈ𼪼°°ÂÊ©¿µ¶¨Ö¹Í´ÁÆÐ§È·ÇУ¬²»Á¼·´Ó¦ÇᣬÔÚºÏÀíÓÃÒ©·¶Î§ÄÚÉñ¾­¶¾ÐÔº±¼û¡£¶Ô賦µÀÖ×Áö½øÊ³À§ÄÑ£¬°éÓжñÐÄÅ»ÍÂÏû»¯µÀÖ¢×´Õߣ¬¿ÉÑ¡Ó÷ÒÌ«ÄáÌù¼Á¡£ßßÌæà¤µÄ´úл²úÎïÖÐÊàÉñ¾­¶¾ÐÔÃ÷ÏÔ£¬ÓÈÆäÊÇ´óÁ¿Ê¹ÓÃʱ£¬ßßÌæà¤Òѱ»ÁÐΪ²»ÍƼöʹÓõݢƬÀàֹʹҩ[1]¡£
3. ÕòÍ´ÁÆÐ§µÄÆÀ¹À¼°ÖÎÁƸöÌ廯£ºÊ¹ÓÃÕòÍ´ÖÎÁƺó£¬ËæÊ±ÆÀ¹ÀÁÆÐ§£¬µ÷ÕûÓÃÒ©¼ÁÁ¿£¬¾¡¿ì½«ÌÛÍ´ÆÀ·Ö¿ØÖÆÔÚ3·ÖÖ®ÄÚ£¬Ã¿ÈÕµÄÍ»·¢Í´¿ØÖÆÔÚ3´ÎÖ®ÄÚ¡£Ä¿Ç°½éÈëÊÖÊõ¶àʹÓþÖÂ飬½éÈëÊõǰÕòÍ´ÖÎÁÆÁ¼ºÃÕߣ¬ÊõÖб¬·¢Í´µÄ¼¸ÂÊÃ÷ÏÔ¼õÉÙ£¬´ÓÎÒÃǵÄÁÙ´²¹Û²ìÖÐÒѵõ½Ö¤Êµ¡£ÏÖÒÑÖð½¥µ­»¯µÚ¶þ½×ÌݵÄÖÎÁÆ£¬¶ÔÖжÈÌÛÍ´¼°ÀÏÄ껼Õߣ¬¿ÉʹÓÃС¼ÁÁ¿°¢Æ¬ÀàÒ©ÎïÆðʼÖÎÁÆ£¬×¢ÖظöÌ廯µ÷Õû[5-6]¡£¶Ô¸ö±ð²¡ÈË£¬Ä³ÖÖÒ©ÎïµÄ²»Á¼·´Ó¦²»ÄÜÄÍÊÜ£¬»òÖ÷¹ÛÒâÔ¸²»Ô¸½ÓÊÜ£¬¿É¸ü»»Ò©Îï¼°¸øÒ©·½·¨£¬Ê¹Ã¿Î»°©Í´»¼Õß½ÓÊܵ½ÊʺÏ×ÔÉíµÄÖÎÁÆ·½·¨¡£
4. ¼°Ê±´¦Àí°¢Æ¬ÀàÒ©ÎïµÄ²»Á¼·´Ó¦£º·þÓð¢Æ¬ÀàÒ©ÎïµÄͬʱ·þÓûºÐº¼Á£¬±ãÃØÊǰ¢Æ¬ÀàÒ©Îï×î³£¼ûµÄ²»Á¼·´Ó¦[1]¡£Ïû»¯µÀÖ¢×´Ã÷ÏÔÕߣ¬×öÊʵ±µÄ¶ÔÖ¢´¦Àí£¬¸øÒÔֹͼÁ»ò¸Ä±ä¸øÒ©Í¾¾¶¡£ÊÈ˯ÑÏÖØÕߣ¬¾¯ÌèÊÇ·ñÓÃÒ©¹ýÁ¿¡£ÎÒÃǵÄÁÙ´²ÖÎÁÆÖУ¬Î´¼ûºôÎüÒÖÖÆ¼°ÆäËûÑÏÖØ²»Á¼·´Ó¦¡£Ä¿Ç°Éв»Ã÷È·ÊÇ·ñÓëÎÒÃÇÓÐʱÓÃÒ©Æ«ÓÚ±£ÊØÓйء£ÕÆÎÕÕòÍ´ÖÎÁƵij߶ȣ¬¼´Òª³ä·ÖÕòÍ´£¬ÓÖÒªËæÊ±µ÷Õû¼ÁÁ¿£¬´¦Àí²»Á¼·´Ó¦£¬°ÑÕòÍ´ÖÎÁÆÕâÒ»ÁÙ´²³£¼û¡¢¿´ËƼòµ¥¡¢µ«ºÜÖØÒªµÄ¹¤×÷×öºÃ¡£

²Î¿¼ÎÄÏ×
1 ËïÑ࣬¹ËοƼ. °©Ö¢Èý½×ÌÝֹʹָµ¼Ô­Ôò[M]. µÚ¶þ°æ.±±¾©£º±±¾©Ò½¿Æ´óѧ³ö°æÉç. 2002£º1-5.
2Äôä]£¬ÁõÊç¿¡£¬Û¡Á¢¾ü,µÈ. °©Í´¼°Æä¶Ô°©Ö¢»¼ÕßÉú»îÖÊÁ¿Ó°ÏìµÄµ÷²é[J]. ÖлªÖ×ÁöÔÓÖ¾, 2000,5:432-434.
3 WHO.Medical nedd for opioid analgesics. In:WHO,ed. Achieving balance in national opioids control policy: guidelines for assessment. Geneva: WHO,2000£º3-4.
4ÓÚÊÀÓ¢£¬ËïÑ࣬ÎâÒ»Áú£¬µÈ. ·ÒÌ«Äá͸ƤÌù¼ÁÖÎÁÆ4492Àý°©Í´µÄÁÙ´²ÁÆÐ§·ÖÎö[J]. ÖлªÖ×ÁöÔÓÖ¾, 2005,6:369-372.
5 Colleau SM. Pain in the elderly with cancer[J]. Cancer Pain Release, 2000,13:1-4.
6  Yu SY. Transdemal fentanyl for the treatment of cancer pain: a multicenter study[J]. Chinese-German J Clin Oncol, 2003,2:114-117.



TAG: ½éÈëÖÎÁÆ ÌÛÍ´ ¶ñÐÔÖ×Áö ÕòÍ´ÖÎÁÆ
 

ÆÀ·Ö£º0

ÎÒÀ´ËµÁ½¾ä

seccode

δ¾­¡¶µ±´úҽѧ¡·ÔÓÖ¾ÉçÊéÃæÍ¬Ò⣬²»µÃ×ªÔØ±¾¿¯ÎÄÕ¡£
»¶Ó­PR>4»òÈÕIP>2000µÄҽѧÀàÍøÕ¾½»»»Á´½Ó£¬QQ£º32622896
¿áվĿ¼£¬ÊÕ¼¸÷ÀàÓÅÐãÍøÕ¾